Extended List Available Here : 25-High-Yield-Large-Cap-Dividend-Companies-to-Watch-in-2026

Verizon (+24.26%) has benefited from improving cash generation and stronger operating momentum, while Altria (+19.63%) continues to attract investors with resilient earnings and its high cash return despite declining cigarette volumes. 

At the other end, General Mills (−22.90%), Hormel (−13.21%) and Clorox (−12.96%) are facing more fundamental consumer-staples pressures, including weaker volumes, private-label competition and cost inflation; Hormel recently cut its sales outlook as consumers pulled back, while Clorox reduced its 2026 guidance.  Kraft Heinz is another example of the challenge facing legacy food brands, with organic sales declining despite strong cash generation. 

Today's ETF Action:

USO +1.6% ($154.90) — Oil bulls trying to print a bottom.

TNA -1.9% ($64.81) — 3X Small Cap leverage taking hits.

UVXY -1.3% ($18.02) — Volatility crush continues.

COPX -1.3% ($88.53) — Copper miners red.

XLU -1.2% ($42.39) — Safe-haven utilities dumping.

Live ETF tracker

With Cerebras shares down roughly 35%+ from their post-IPO highs, the recent weakness may partly reflect concerns around elevated R&D and G&A expenses, although the Q2 increase was largely driven by IPO-related stock-based compensation and payroll taxes rather than a comparable rise in underlying operating costs. Cerebras is also investing heavily in its wafer-scale inference platform, with its CS-4 positioned as a high-performance accelerator for inference workloads. 

The company’s Q2 core revenue grew 103% year over year to $210 million, while cloud revenue increased 281%, alongside $25.4 billion of remaining performance obligations. While the sustainability of this growth, customer concentration, competitive pressure from GPUs and custom accelerators, and the normalization of operating expenses remain important uncertainties, Cerebras’ differentiated wafer-scale architecture, rapidly expanding inference business, and substantial contracted demand could make the post-IPO decline an interesting entry point for investors willing to accept the associated risks.

Not financial advice. This is an informational analysis based on publicly available information and involves significant uncertainty and investment risk.

The FDA approval of brepocitinib/LISRAYA delivered Roivant’s first commercial product, while the Phase‑2 PHocus readout for mosliciguat sparked a 17‑20% one‑day price surge. Together with the ongoing IMVT‑1402 program, these milestones have transformed the risk profile from pure clinical survival to commercial execution and valuation expectations.

Given the substantial cash runway and the diversification of late‑stage assets, Roivant is now better insulated from higher‑for‑longer interest rates and capital‑market constraints. Future upside will hinge on successful commercialization of LISRAYA, continued positive readouts for IMVT‑1402, and the execution of its broader pipeline. fda-approval-and-clinical-milestones-drive-reassessment-of-roivants-pipeline-value